338 results on '"Vokes, E.E."'
Search Results
2. Neutrophil-to-Lymphocyte Ratio Kinetics and Survival with Neoadjuvant Immuno-chemotherapy and Response-Stratified Chemoradiation in Locoregionally Advanced Head and Neck Cancer
3. Phase I/II Study of A Novel MDM-2 Inhibitor (APG-115-Alrizomadlin) in p53 Wild Type Salivary Gland Cancers
4. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
5. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
6. OA22.03 The Addition of Multisite SBRT to Ipilimumab and Nivolumab in First Line Metastatic NSCLC: The COSINR Trial
7. Radiomics Based Assessment of Tumor Infiltrating CD8 T-Cells Predicts Induction Systemic Therapy Response in HPV+ Oropharyngeal Cancer: Exploratory Analysis of Prospective Trials
8. Involved Site Radiotherapy in HPV Positive Oropharyngeal Cancer: Patterns of Failure Analysis Across Prospective De-Escalation Trials
9. Long-Term Results of Induction Chemotherapy Followed by 50 Gy Radiation Therapy Alone for Low-Risk HPV-Positive Oropharynx Cancer
10. Concurrent Radiation and Immunotherapy Augments Local Immunity and Improves Survival in Aneuploid NSCLC
11. Definitive Chemoradiotherapy for Salivary Gland Cancers
12. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
13. “Timing is Everything”: the evolving role of immune checkpoint inhibition in nasopharyngeal carcinoma
14. Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer
15. Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer
16. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
17. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades
18. 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer
19. Cell-Free HPV DNA Kinetics Predicted by Radiographic Response in Locoregional Viral-Associated Oropharyngeal Cancer Receiving Response-Adaptive Treatment – Exploratory Analysis of a Prospective Trial
20. Radiation Dose and Volume De-Escalation for High-Risk HPV Positive Oropharyngeal Cancer
21. Assessment of Tumor Burden and Response by RECIST vs. Volume Change in HPV+ Oropharyngeal Cancer – An Exploratory Analysis of Prospective Trials
22. 1546P Impact of stratification factors on outcomes in limited-stage small cell lung cancer: Analysis of CALGB 30610 (Alliance)/RTOG 0538
23. The Impact of Age and Tumor Volume on Volumetric Systemic Therapy Response in HPV-Positive Oropharyngeal HNSCC – A Pooled Analysis of Prospective Trials
24. Dosimetric Predictors of Hypothyroidism after Combined Modality Therapy ± Immunotherapy for HPV-Related Oropharyngeal Cancer: A Secondary Analysis of Prospective Trials
25. 944TiP Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1–positive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial
26. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA
27. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma
28. Omission of the Pathologic Node-Negative Neck From Postoperative Radiation Therapy for Oral Cavity Cancer
29. Organ Preservation with Definitive Chemoradiotherapy for T4 Laryngeal Squamous Cell Carcinoma
30. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck
31. A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers
32. Mature Outcomes of 61.2 Gy Concomitant Boost (CB) Thoracic Radiotherapy (TRT) in Limited Stage Small Cell Lung Cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538
33. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC
34. Organ Preservation With Definitive Chemoradiotherapy for T4 Laryngeal Squamous Cell Carcinoma
35. 867P A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
36. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
37. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels
38. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma
39. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
40. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
41. Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer
42. Toxicity and Efficacy of Stereotactic Body Radiotherapy plus Nivolumab with Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors
43. Feasibility Of Next-Generation Genomic Sequencing To Identify Prognostic Biomarkers Of Chemoradiation Response For Salivary Gland Malignancies
44. Safety and Efficacy of a Randomized Phase I Trial to Evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-small Cell Lung Cancer (COSINR Study)
45. Low risk HPV associated oropharyngeal squamous cell carcinoma treated with induction chemoimmunotherapy followed by TORS or radiotherapy
46. Résultats à 5 ans des essais cliniques randomisés de phase III CheckMate (CM) 017/057 : nivolumab vs docétaxel dans le cancer bronchique non à petites cellules (CBNPC) avancé après un traitement antérieur
47. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus
48. Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer
49. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience
50. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.